Bond.az White LogoBond.az Black Logo

Piper Sandler cuts Boot Barn target on guidance

Piper Sandler lowered Boot Barn price target to $226 from $230, maintaining Overweight. Q4 results beat, FY2027 guidance implies EPS growth up to 18%. Stock down 17% YTD.

William Thomas
ByWilliam Thomas- Senior Editor
|
0

Piper Sandler lowered its price target on Boot Barn Holdings Inc. (NYSE:BOOT) to $226 from $230, maintaining an Overweight rating.

The update follows Boot Barn's fourth-quarter results and fiscal 2027 guidance. The company posted comparable sales growth that beat expectations in Q4.

Boot Barn's first quarter is off to a solid start, with comparable sales up 5% through the first six weeks. Sales strength is broad-based across categories.

The retailer has not observed weakness across income cohorts despite higher gas prices. Fiscal 2027 guidance calls for EPS growth of up to 18% at the high end, versus an average of 24% over the past two years.

Boot Barn shares have fallen 17% year-to-date trading at $149.11 with a P/E of 20.79. The stock trades at a low P/E relative to near-term earnings growth with a PEG ratio of 0.83. The company has initiatives to drive comparable sales growth and product margin expansion.

In other news, Boot Barn reported fiscal Q4 2026 earnings that beat expectations: EPS $1.45 vs. $1.43 estimate, revenue $539M vs. $533.1M. BTIG reiterated a Buy rating and $235 target. Williams Trading cut its target to $202 from $236 but maintained a Buy rating.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
841

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...